INmune Bio Inc (INMB)
11.32
+0.83
(+7.91%)
USD |
NASDAQ |
May 15, 16:00
11.32
0.00 (0.00%)
After-Hours: 16:14
INmune Bio Total Liabilities (Quarterly): 17.81M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 17.81M |
| December 31, 2023 | 18.86M |
| September 30, 2023 | 17.97M |
| June 30, 2023 | 19.07M |
| March 31, 2023 | 18.68M |
| December 31, 2022 | 21.69M |
| September 30, 2022 | 20.09M |
| June 30, 2022 | 17.88M |
| March 31, 2022 | 18.71M |
| December 31, 2021 | 19.72M |
| September 30, 2021 | 19.42M |
| June 30, 2021 | 17.47M |
| Date | Value |
|---|---|
| March 31, 2021 | 2.312M |
| December 31, 2020 | 1.902M |
| September 30, 2020 | 1.610M |
| June 30, 2020 | 1.363M |
| March 31, 2020 | 1.271M |
| December 31, 2019 | 0.8605M |
| September 30, 2019 | 0.687M |
| June 30, 2019 | 0.6927M |
| March 31, 2019 | 0.7809M |
| December 31, 2018 | 0.8238M |
| September 30, 2018 | 0.2114M |
| December 31, 2017 | 0.3097M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
0.687M
Minimum
Sep 2019
21.69M
Maximum
Dec 2022
11.90M
Average
17.84M
Median
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.799B |
| Sarepta Therapeutics Inc | 2.263B |
| Dare Bioscience Inc | 26.33M |
| Zevra Therapeutics Inc | 102.46M |
| Kodiak Sciences Inc | 213.59M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 46.83M |
| Shareholders Equity (Quarterly) | 29.02M |
| Debt to Equity Ratio | 0.2569 |
| Current Ratio | 1.709 |
| Net Debt Paydown Yield | 0.69% |